- Home
- NUVL vs PVH Comparison
NUVL vs PVH Comparison
Compare NUVL & PVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- PVH
- Stock Information
- Founded
- NUVL 2017
- PVH 1881
- Country
- NUVL United States
- PVH United States
- Employees
- NUVL N/A
- PVH N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- PVH Apparel
- Sector
- NUVL Health Care
- PVH Consumer Discretionary
- Exchange
- NUVL Nasdaq
- PVH Nasdaq
- Market Cap
- NUVL 6.7B
- PVH 6.1B
- IPO Year
- NUVL 2021
- PVH N/A
- Fundamental
- Price
- NUVL $75.84
- PVH $92.83
- Analyst Decision
- NUVL Strong Buy
- PVH Buy
- Analyst Count
- NUVL 11
- PVH 16
- Target Price
- NUVL $112.36
- PVH $129.63
- AVG Volume (30 Days)
- NUVL 558.9K
- PVH 900.2K
- Earning Date
- NUVL 02-25-2025
- PVH 12-04-2024
- Dividend Yield
- NUVL N/A
- PVH 0.16%
- EPS Growth
- NUVL N/A
- PVH 45.85
- EPS
- NUVL N/A
- PVH 12.35
- Revenue
- NUVL N/A
- PVH $8,771,200,000.00
- Revenue This Year
- NUVL N/A
- PVH N/A
- Revenue Next Year
- NUVL N/A
- PVH $1.22
- P/E Ratio
- NUVL N/A
- PVH $7.51
- Revenue Growth
- NUVL N/A
- PVH N/A
- 52 Week Low
- NUVL $61.80
- PVH $88.60
- 52 Week High
- NUVL $113.51
- PVH $141.15
- Technical
- Relative Strength Index (RSI)
- NUVL 38.09
- PVH 29.73
- Support Level
- NUVL $69.58
- PVH $88.60
- Resistance Level
- NUVL $78.18
- PVH $101.72
- Average True Range (ATR)
- NUVL 3.03
- PVH 3.42
- MACD
- NUVL 0.04
- PVH -1.53
- Stochastic Oscillator
- NUVL 50.40
- PVH 19.88
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About PVH PVH Corp.
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites and about 1,500 stores, licenses its brands to third parties, and distributes its merchandise through department stores and other wholesale accounts. The firm traces its history to 1881 and is based in New York City.